Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Bernard Escudier; Camillo Porta; Manuela Schmidinger; Nathalie Rioux‐Leclercq; Axel Bex; Vincent Khoo; Viktor Grünwald; Silke Gillessen; Alan Horwich

doi:10.1093/annonc/mdz056

Keywords

MedicineRenal cell carcinomaOncologyCarcinomaClinical PracticeInternal medicineFamily medicine

Affiliated Institutions

Related Publications

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Margaret A. Tempero , Mokenge P. Malafa , Mahmoud M. Al-Hawary +33 more

Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients’ advanced disease...

2021 Journal of the National Comprehensive... 1146 citations

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

Furio Pacini , Martin Schlumberger , Henning Dralle +3 more

Thyroid carcinoma is rare among human malignancies (<1%) but is the most frequent endocrine cancer, accounting for about 5% of thyroid nodules (1). The latter are very freque...

2006 European Journal of Endocrinology 1965 citations

Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns

A. Rose Brannon , Anupama Reddy , Michael Seiler +13 more

Clear cell renal cell carcinoma (ccRCC) is the predominant RCC subtype, but even within this classification, the natural history is heterogeneous and difficult to predict. A sop...

2010 Genes & Cancer 322 citations

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer , B. Yа. Alekseev , Sun Young Rha +35 more

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme;...

2021 New England Journal of Medicine 1597 citations

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.

Charles G. Drake , David F. McDermott , Mario Sznol +10 more

4514 Background: Programmed death-1 (PD-1) is an immune checkpoint receptor that negatively regulates T-cell activation. PD-L1, a PD-1 ligand, has been associated with poor prog...

2013 Journal of Clinical Oncology 55 citations

Publication Info

Year: 2019
Type: article
Volume: 30
Issue: 5
Pages: 706-720
Citations: 1096
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1096

OpenAlex

Cite This

APA Style

                            
                                
                                    Bernard Escudier, 
                                
                                    Camillo Porta, 
                                
                                    Manuela Schmidinger
                                
                                et al.
                            
                            (2019). 
                            Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 
                            Annals of Oncology
                            , 30
                            (5)
                            , 706-720.
                            https://doi.org/10.1093/annonc/mdz056
                        

Identifiers

DOI: 10.1093/annonc/mdz056